Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT05186051
Registration number
NCT05186051
Ethics application status
Date submitted
23/12/2021
Date registered
11/01/2022
Date last updated
11/07/2022
Titles & IDs
Public title
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZYIL1 in Subjects With Cryopyrin Associated Periodic Syndromes (CAPS)
Query!
Scientific title
A Phase 2a, Prospective, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZYIL1 in Subjects With Cryopyrin Associated Periodic Syndromes (CAPS)
Query!
Secondary ID [1]
0
0
ZYIL1.21.001
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Cryopyrin Associated Periodic Syndrome
0
0
Query!
Condition category
Condition code
Human Genetics and Inherited Disorders
0
0
0
0
Query!
Other human genetics and inherited disorders
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Autoimmune diseases
Query!
Skin
0
0
0
0
Query!
Dermatological conditions
Query!
Other
0
0
0
0
Query!
Research that is not of generic health relevance and not applicable to specific health categories listed above
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - ZYIL1 capsule
Experimental: ZYIL1 Capsule - subject will receive 50 mg twice daily (BD) dose for 7 days
Treatment: Drugs: ZYIL1 capsule
NLRP3 inflammasome inhibitor
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Incidence and Severity of Adverse event of ZYIL1
Query!
Assessment method [1]
0
0
The Common Terminology Criteria for Adverse Event (CTCAE) (Version 5.0 or higher) system will be used for reporting and grading
Query!
Timepoint [1]
0
0
Baseline to Day 7
Query!
Secondary outcome [1]
0
0
Maximum concentration (Cmax)
Query!
Assessment method [1]
0
0
Blood samples will be withdrawn on Day 1 and Day 7 to evaluate maximum concentration
Query!
Timepoint [1]
0
0
Pre-dose to Day 7
Query!
Secondary outcome [2]
0
0
To evaluate disease activity scores based on 5 point physician and patient global assessment over 7 days treatment of ZYIL1
Query!
Assessment method [2]
0
0
Physician global assessment on 5 point scale score will be taken
Query!
Timepoint [2]
0
0
Baseline to Day 10
Query!
Secondary outcome [3]
0
0
Time to reach maximum concentration (Tmax)
Query!
Assessment method [3]
0
0
Blood samples will be withdrawn on Day 1 and Day 7 to evaluate Time to reach maximum concentration
Query!
Timepoint [3]
0
0
Pre-dose to Day 7
Query!
Secondary outcome [4]
0
0
Area under the curve for dosing interval(12 hours) AUCtau
Query!
Assessment method [4]
0
0
Blood samples will be withdrawn on Day 1 and Day 7 to evaluate AUCtau
Query!
Timepoint [4]
0
0
Pre-dose to Day 7
Query!
Secondary outcome [5]
0
0
Change in WBC count
Query!
Assessment method [5]
0
0
Blood samples will be collected from pre-dose till Day 10 to evaluate the change
Query!
Timepoint [5]
0
0
Baseline to Day 10
Query!
Secondary outcome [6]
0
0
Change in IL-1ß
Query!
Assessment method [6]
0
0
Blood samples will be collected from pre-dose till Day 10 to evaluate the change
Query!
Timepoint [6]
0
0
Baseline to Day 10
Query!
Secondary outcome [7]
0
0
Change in Serum amyloid protein A
Query!
Assessment method [7]
0
0
Blood samples will be collected from pre-dose till Day 10 to evaluate the change
Query!
Timepoint [7]
0
0
Baseline to Day 10
Query!
Secondary outcome [8]
0
0
Change in IL-6
Query!
Assessment method [8]
0
0
Blood samples will be collected from pre-dose till Day 10 to evaluate the change
Query!
Timepoint [8]
0
0
Baseline to Day 10
Query!
Secondary outcome [9]
0
0
Change in CRP
Query!
Assessment method [9]
0
0
Blood samples will be collected from pre-dose till Day 10 to evaluate the change
Query!
Timepoint [9]
0
0
Baseline to Day 10
Query!
Eligibility
Key inclusion criteria
1. Subjects with a confirmed diagnosis of CAPS (FCAS, NOMID, or MWS) aged 18 to 75 years
inclusive at screening A confirmed diagnosis of CAPS comprises the following:
1. Subject has previously experienced at least 2 typical clinical symptoms of CAPS
(may include urticarial skin rash, myalgia, arthralgia, recurrent fever,
fatigue/malaise, headache, conjunctivitis, and any other autoinflammatory
symptom); and
2. Documented verification of a genetic mutation in NLRP3.
2. Positive response of ZYIL1 in inhibiting secreted IL-1ß from peripheral blood
mononuclear cells isolated from the subject's blood treated with LPS ex vivo showing
half maximal inhibitory concentration below 500 nM.
3. Subject must be willing to discontinue current anti-IL-1 treatment prior to study drug
dosing if applicable.
4. Subject must demonstrate flaring of CAPS de novo or after discontinuation of anti-IL-1
inhibitor treatment. Flaring is defined as worsening of disease activity as per
physician global assessment of disease activity with elevation of CRP (>2 x upper
limit of normal [ULN]).
5. Subject must have a body mass index (BMI) between =18.0 and =38.0 kg/m2 at Screening.
6. Female subject of reproductive age must be non-pregnant and non-lactating, and must
use an acceptable, highly effective contraception from screening until 1 month after
the last dose of study drug.
7. Male subject must be willing to use contraception and must not donate sperm for at
least 90 days after the last dose of study drug.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
75
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Any severe, progressive, or uncontrolled medical condition within the past 3 months
that might have impact on the clinical trial as per the investigator's discretion.
2. Use of any investigational drug or investigational medical device or participation in
other clinical study within 4 weeks prior to Screening or 5 half- lives of the product
(whichever is longer).
3. Any clinically significant laboratory or ECG findings during the screening in the
opinion of the Investigator.
4. Estimated glomerular filtration rate (eGFR) < 90 mL/min/1.73m2, as measured by the
Cockcroft-Gault equation at screening
5. Total bilirubin above upper limit of normal (ULN) or AST(SGOT)/ALT(SGPT) > 1.5 times
of ULN at screening
6. QT interval corrected for heart rate using Fridericia's method (QTcF) > 450 msec at
screening
7. History of clinically significant hypersensitivity, intolerance, or allergies, as
determined by the investigator.
8. History of fever, cough or any other active systemic infections within 2 weeks prior
to receiving study drug.
9. History or presence of alcohol abuse (alcohol consumption more than 40 g/4
units/4standard drinks per day), or drug habituation, or any prior intravenous usage
of an illicit substance
10. Surgery within last 3 months or planned major surgery within next 3 months from the
date of screening (other than minor cosmetic surgery and minor dental surgery).
11. Subjects who have donated one unit (490 mL) of blood in the past 3 months.
12. Use or intend to use any medications/products known to alter drug absorption,
metabolism, or elimination processes including St John's Wort within 4 weeks prior to
receiving study drug and up to end of study. Use of such medication will be considered
on a case-by-case basis as per the opinion of the investigator and/or independent
medical monitor, or use of grapefruit or similar substances (Seville oranges or
marmalade, grapefruit juice, grapefruit hybrids, pomelos, exotic citrus fruits or
fruit juices) within 7 days prior to the Run-in period.
13. Use or intend to use any over-the-counter (vitamins, minerals, and
phytotherapeutic/herbal/plant-derived preparations) or prescription medications within
7 days or 5 half-lives (whichever is longer) prior to receiving study drug, with the
exception of hormone replacement therapy and therapies for chronic stable diseases
that have been stable for at least 30 days prior to screening and until Day 1, unless
deemed acceptable by the investigator
14. History of or positive screening test for hepatitis C infection (defined as positive
for hepatitis C virus antibody), hepatitis B infection (defined as positive for
hepatitis B surface antigen), or human immunodeficiency virus I or II.
15. Female subjects who are pregnant, currently breastfeeding, or attempting to conceive.
16. Any disorder that, in the Investigator's opinion, may interfere with study compliance,
such as significant mental, nervous disorder or other illness. In making this
assessment, the Investigator must refer to the study information provided including
the Investigator's Brochure.
17. Inability to be venipuncture or tolerate venous puncture.
18. Any condition or abnormal baseline findings that in investigator's judgment might
increase the risk to the subject or decrease the chance of obtaining satisfactory data
needed to obtain the objective of the study.
19. Other unspecified reasons that, in the opinion of the investigator make the subject
unsuitable for the study.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/06/2022
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
2/07/2022
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
3
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Department of Clinical Immunology and Allergy - Adelaide
Query!
Recruitment postcode(s) [1]
0
0
5000 - Adelaide
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Zydus Lifesciences Limited
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
ZYIL1 is expected to show benefit in patients with CAPS. The present study aims to determine
the safety, tolerability, pharmacokinetics, and pharmacodynamics of ZYIL1 when administered
to subjects with CAPS.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT05186051
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Dr Deven Parmar, MD
Query!
Address
0
0
Cadila Healthcare Ltd.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT05186051
Download to PDF